The objective of the CLC Genomics Workbench is to create an integrated bioinformatics environment which combines the power to handle the magnitude of NGS data with a carefully designed graphical user interface.įor the first version we have focused on handling the secondary level of NGS bioinformatics, namely de novo assembly and reference assembly.
Clc genomics workbench snp detection full#
However, we have also included some tertiary analyses like SNP detection and graphical identification of large scale genomic events.įor a full feature list, have a look here. Smoother handling of hybrid data sets (cross-platform, cross-experiment-design)Īlongside Genomics WB 2.0, we are also releasing a command line program package for de novo and reference assembly which will give users access to these tools in a scripting environment.A completely new short read assembler delivering the worlds fastest reference assembly – click here for more info and white paper.This includes the following improvements: Version 2.0 of the software is out in a few days, and for this release we have focused on bringing our Workbench to a state where it can comfortably handle human genome size data sets. This package is a separate product which includes the fast assembly algorithms and a number of utilities for handling assembly results.
Improved detection of genome scale eventsįurther down the line we are looking at including features like.Advanced feature queries – feature tracks.Having established a firm basis for secondary analysis we have an ambitious roadmap for including more tertiary analysis tools later this year. However, although we intend to provide a very comprehensive tool set we know that we can not cover all applications there is. For this reason, we are focusing on providing an open industry-strength platform that users can modify and extend.
For this reason we provide a Software Developer Kit which gives access to an extensive and well supported API and a developer community. I hope this was of help and please feel free to post any questions or comments to this that you may have.
0 kommentar(er)
